IQVIA (NYSE:IQV – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.
Insider and Institutional Ownership
89.6% of IQVIA shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 1.7% of IQVIA shares are held by insiders. Comparatively, 14.7% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of current ratings for IQVIA and Bullfrog AI, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IQVIA | 0 | 3 | 13 | 1 | 2.88 |
| Bullfrog AI | 1 | 1 | 0 | 0 | 1.50 |
Profitability
This table compares IQVIA and Bullfrog AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IQVIA | 8.10% | 30.25% | 6.54% |
| Bullfrog AI | N/A | -150.36% | -127.98% |
Earnings and Valuation
This table compares IQVIA and Bullfrog AI”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IQVIA | $16.31 billion | 2.74 | $1.36 billion | $8.06 | 33.67 |
| Bullfrog AI | $120,000.00 | 92.70 | -$6.50 million | ($0.46) | -1.30 |
IQVIA has higher revenue and earnings than Bullfrog AI. Bullfrog AI is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
IQVIA has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.71, meaning that its share price is 371% less volatile than the S&P 500.
Summary
IQVIA beats Bullfrog AI on 13 of the 15 factors compared between the two stocks.
About IQVIA
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
